193 related articles for article (PubMed ID: 34788626)
21. Impact of accumulated alterations in driver and passenger genes on response to radiation therapy.
Seo Y; Tamari K; Takahashi Y; Minami K; Isohashi F; Suzuki O; Sumida I; Ogawa K
Br J Radiol; 2020 May; 93(1109):20190625. PubMed ID: 32031414
[TBL] [Abstract][Full Text] [Related]
22. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.
Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A
Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300
[No Abstract] [Full Text] [Related]
23. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
24. Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
Xiao Q; Sun Y; Dobi A; Srivastava S; Wang W; Srivastava S; Ji Y; Hou J; Zhao GP; Li Y; Li H
Sci Rep; 2018 Aug; 8(1):12868. PubMed ID: 30150711
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive molecular and clinical characterization of SLC1A5 in human cancers.
Zhang H; Cui K; Yao S; Yin Y; Liu D; Huang Z
Pathol Res Pract; 2021 Aug; 224():153525. PubMed ID: 34171602
[TBL] [Abstract][Full Text] [Related]
26. The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.
Salomon MP; Wang X; Marzese DM; Hsu SC; Nelson N; Zhang X; Matsuba C; Takasumi Y; Ballesteros-Merino C; Fox BA; Barkhoudarian G; Kelly DF; Hoon DSB
Clin Cancer Res; 2018 Sep; 24(17):4126-4136. PubMed ID: 30084836
[No Abstract] [Full Text] [Related]
27. MethCNA: a database for integrating genomic and epigenomic data in human cancer.
Deng G; Yang J; Zhang Q; Xiao ZX; Cai H
BMC Genomics; 2018 Feb; 19(1):138. PubMed ID: 29433427
[TBL] [Abstract][Full Text] [Related]
28. Genetic and Epigenetic Characterization of Growth Hormone-Secreting Pituitary Tumors.
Välimäki N; Schalin-Jäntti C; Karppinen A; Paetau A; Kivipelto L; Aaltonen LA; Karhu A
Mol Cancer Res; 2019 Dec; 17(12):2432-2443. PubMed ID: 31578227
[TBL] [Abstract][Full Text] [Related]
29. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
30. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.
Shen C; Meric-Bernstam F; Su X; Mendelsohn J; Giordano S
Oncotarget; 2016 Nov; 7(44):71686-71695. PubMed ID: 27634896
[TBL] [Abstract][Full Text] [Related]
32. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract][Full Text] [Related]
33. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer characterization of long non-coding RNA and DNA methylation mediated transcriptional dysregulation.
Yang Z; Xu F; Wang H; Teschendorff AE; Xie F; He Y
EBioMedicine; 2021 Jun; 68():103399. PubMed ID: 34044218
[TBL] [Abstract][Full Text] [Related]
35. Pan-cancer driver copy number alterations identified by joint expression/CNA data analysis.
Wang G; Anastassiou D
Sci Rep; 2020 Oct; 10(1):17199. PubMed ID: 33057153
[TBL] [Abstract][Full Text] [Related]
36. Multi-omics characterization and validation of MSI-related molecular features across multiple malignancies.
Zheng Y; Huang Y; Bi G; Du Y; Liang J; Zhao M; Chen Z; Zhan C; Xi J; Wang Q
Life Sci; 2021 Apr; 270():119081. PubMed ID: 33516699
[TBL] [Abstract][Full Text] [Related]
37. Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors.
Martin-Trujillo A; Vidal E; Monteagudo-Sánchez A; Sanchez-Delgado M; Moran S; Hernandez Mora JR; Heyn H; Guitart M; Esteller M; Monk D
Nat Commun; 2017 Sep; 8(1):467. PubMed ID: 28883545
[TBL] [Abstract][Full Text] [Related]
38. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
39. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
Zhang Y; Zhu B; Cai Y; Zhu S; Zhao H; Ying X; Jiang C; Zeng J
BMC Cancer; 2022 Jan; 22(1):2. PubMed ID: 34980012
[TBL] [Abstract][Full Text] [Related]
40. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
